ASCO 2020：11项中国研究获选口头报告，17项Poster报告

曾受全球新冠疫情曾受到影响，原定于5月底29日~6月底2日在纽约举行的加拿大外科学时会（ASCO）高峰时会今年将首次以线上表达方式协办，这是在此之前最大规模的线上盛时会。以前，联席时会议的参考资料选择题披露，共约103个sessions，之前国共约有11项学术研究入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

衍生物替尼或拉帕替尼加卡培他松用以HER2+心肌梗死乳腺恶连续性肿糙（PHOEBE）：一项III期随机试验之前。

首站：心肌梗死乳腺恶连续性肿糙

所作：北京协和医学院的医院徐兵河系主任、马飞系主任，复旦大学附属的医院胡夕春系主任等

参考资料号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可开刀三比如说乳腺恶连续性肿糙标准治疗法后卡培他松维持节拍肌肉注射的III期试验之前（SYSUCC-001）。

首站：乳腺恶连续性肿糙—大面积/区域/来进行治疗法

所作：之前山大学防治之前心王树森系主任等

参考资料号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用心肌梗死脑组织的表现型特征来得出结论脑组织脊液之前循环DNA检测的概率: 新工具对抗外公对手

首站：新工具化解外公问题

所作：郑美芹 郑科克等

参考资料号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为之前后期肠胃巨噬细胞恶连续性肿糙的之前路治疗法：一项开放标签、随机、多之前心II/III期试验之前。

首站：消化道恶连续性肿糙—十二指肠静脉、胰腺和肠胃胆

所作：复旦大学华西的医院毕锋系主任、之前国民主自由解放军八一的医院秦叔逵系主任等

参考资料号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

之前国之前后期肠胃恶连续性肿糙症状阿帕替尼二线治疗法：一项随机、安慰剂相符合、双盲III期学术研究

首站：消化道恶连续性肿糙—十二指肠静脉、胰腺和肠胃胆

所作：之前国民主自由解放军八一的医院秦叔逵系主任、复旦大学华西的医院郑秋系主任等

参考资料号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

之前后期病情恶化连续性卵巢恶连续性肿糙二次巨噬细胞减灭术的一项随机III期试验之前：SOC1 / SGOG-OV2。

栏目：妇科恶连续性肿糙症

所作：复旦大学附属之前山的医院臧荣余系主任等

参考资料：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈恶连续性肿糙根治连续性阴囊切除术后来进行治疗法之前的序贯放肌肉注射对比单独PET或定时放肌肉注射（STARS学术研究）：一项随机、相符合、开放标签的III期试验之前。

联席时会议：妇科恶连续性肿糙症

所作：之前山大学防治之前心黄鹤系主任、刘继红系主任等

参考资料号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：来进行吉非替尼对比肌肉注射用以可切除的EGFR突变的N1-N2期NSCLC-随机III期外科试验之前的最终总体存活量化。

栏目：心肌梗塞—非小巨噬细胞大面积-区域/小巨噬细胞/其他背部

所作：广东省民主自由的医院吴一龙系主任等

参考资料号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变寡转移非小巨噬细胞心肌梗塞症状之前路乙酰磷酸化酶抑制剂重新组建或不重新组建积极前线大面积PET：III期开放标签外科随机试验之前（SINDAS）的之前期结果（NCT02893332）。

栏目：心肌梗塞-非小巨噬细胞转移

所作：绵阳市民主自由的医院曾铭系主任等

参考资料：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序连续性死亡-1（PD-1）的人源化IgG4制剂重新组建阿昔替尼用以心肌梗死黏膜黑色素糙症状的Ib期学术研究的总存活期和生物标志物量化。

栏目：黑色素糙/细菌连续性

所作：北京大学的医院郭军、盛锡楠系主任等

参考资料：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的稳定连续性和结果：国际标准化组织CAR-T巨噬细胞首次体液试验之前治疗法病情恶化/难治连续性T巨噬细胞急连续性淋巴巨噬细胞前列腺癌（r/r T-ALL）的稳定连续性和。联席时会议：开发之前的治疗法技术-免疫治疗法。所作：王欣欣等参考资料：3013标语：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在之前后期静脉楔形巨噬细胞恶连续性肿糙症状之前的运用：一项随机的开放标签II期试验之前（ORIENT-2）。联席时会议：消化道恶连续性肿糙-十二指肠静脉恶连续性肿糙、胰腺恶连续性肿糙和肠胃胆道恶连续性肿糙所作：徐建明系主任等参考资料：4511标语：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D选择连续性CAR-T巨噬细胞对髓母巨噬细胞糙的根除连续性治疗法联席时会议：之前枢神经系统所作：代红久、孙斌、杨东、徐晖、郑晶晶、魏佳、赵旭东参考资料：2522标语。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在之前后期错配修复瑕疵症状之前的运用联席时会议：开发之前的治疗法学-免疫治疗法所作：沈琳系主任等参考资料：3021标语。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART治疗法病情恶化/难治连续性ACUTE淋巴巨噬细胞前列腺癌/淋巴糙的首例体液外科试验之前联席时会议: 开发连续性治疗法学-免疫治疗法所作简介：张明志，杨林等参考资料：3026标语: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 罗勒替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）重新组建运用以之前后期实质上糙症状的Ib期学术研究联席时会议：发展连续性治疗法学--水分子靶向药品和生物学所作：龚继芳，沈琳系主任等参考资料：3523标语：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin重新组建萘和nedaplatin治疗法病情恶化连续性或心肌梗死静脉楔形巨噬细胞恶连续性肿糙（ESCC）症状的II期学术研究。联席时会议：消化道恶连续性肿糙-十二指肠静脉、胰腺和肠胃胆道恶连续性肿糙的学术研究所作：王志弱，郑玉红，王德申，王凤华，任超，谭琼 王志弱、郑玉红、王德深、王凤华、任超、谭琼参考资料：4522标语：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.联席时会议：消化道恶连续性肿糙-十二指肠静脉恶连续性肿糙、胰腺恶连续性肿糙和肠胃胆管恶连续性肿糙的二线治疗法所作：宋艳等参考资料：4524标语：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿外体外侧RNA特征向量用以初始活检时检测高等级恶连续性肿糙的尿外体外侧RNA特征向量：一项多之前心的回顾连续性学术研究联席时会议：泌尿生殖系统恶连续性肿糙症---恶连续性肿糙、皮肤恶连续性肿糙和恶连续性肿糙所作简介：Liaoyuan Li等参考资料：5522标语。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 大面积之前后期宫颈恶连续性肿糙并发肌肉注射后的来进行肌肉注射联席时会议: 妇科恶连续性肿糙症所作简介： 郑珉珉等参考资料：6031标语：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼治疗法甲状腺髓连续性恶连续性肿糙的相关连续性：基于ALTER01031试验之前的量化。时会话：黑纹所作：唐山市的医院用心系主任参考资料：6526标语。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、形状和成年对安洛替尼治疗法后症状结局的曾受到影响: ALTER01031的亚组量化联席时会议：黑纹所作：唐山市的医院用心系主任参考资料：6527标语。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA量化得出结论I-IIIA期非小巨噬细胞心肌梗塞（NSCLC）症状术后病情恶化: GASTO1035和GASTO1018的结果联席时会议：心肌梗塞-非小巨噬细胞大面积-区域连续性/小巨噬细胞/小巨噬细胞/其他胸科恶连续性肿糙症所作：Si-Yu Wang等参考资料：9023标语：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小巨噬细胞心肌梗塞（NSCLC）之前EGFR乙酰磷酸化酶抑制剂的新型耐药机制联席时会议:心肌梗塞-非小巨噬细胞心肌梗死心肌梗塞所作简介：赵昕，金结缘，满宇，欧秋香，华宝，薛武，杨少，范敏 赵昕、金结缘、满宇、欧秋香、华宝、薛武、杨绍、范敏参考资料：9528标语：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验之前之前之前后期黑色素糙总存活的替代终点联席时会议：黑色素糙/细菌连续性所作：聂润聪，袁书弱，郑元芳，陈英波，周志伟 聂润聪、袁书弱、郑元芳、陈英波、周志伟参考资料：10030标语：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼治疗法病情恶化或心肌梗死原发连续性恶连续性骨症状的II期学术研究联席时会议： 肉糙所作：唐丽娜，牛晓辉，郑德，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶参考资料：11525标语。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在之前后期肉糙症状多线治疗法之前的稳定连续性和。联席时会议：肉糙所作：姚伟涛，来由弱，张鹏，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、来由弱、张鹏、王鑫、杜鑫辉、田志超、牛晓英参考资料：11526标语：414